Medpace Cash Flow Statement
NASDAQ: MEDPHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Medpace free cash flow
In fiscal 2025, Medpace generated $713.2 million of operating cash flow and spent $31.4 million on capital expenditures. That left free cash flow of $681.9 million, a free-cash-flow margin of 26.9% of revenue. Free cash flow was up 19.2% from the prior year's $572.3 million.
Medpace returned $917.4 million to shareholders through share repurchases, equal to 135% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
Medpace cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 451.12M | 404.39M | 282.81M | 245.37M | 181.85M | 145.38M | 100.44M | 73.19M | 39.12M | 13.43M |
| Net Income growth (YoY) | +11.56% | +42.99% | +15.26% | +34.93% | +25.08% | +44.74% | +37.25% | +87.07% | +191.41% | — |
| Depreciation & Amortization | 27.18M | 27.81M | 24.13M | 18.99M | 16.00M | 11.65M | 8.36M | 9.24M | 8.57M | 7.44M |
| Stock-Based Compensation | 34.79M | 25.51M | 20.52M | 21.41M | 14.47M | 13.78M | 20.74M | 6.50M | 4.46M | 9.81M |
| Change in Working Capital | 110.20M | 154.79M | 134.97M | 99.90M | 82.88M | 75.79M | 42.50M | 37.68M | 4.81M | 2.54M |
| Operating Cash Flow | 713.22M | 608.82M | 433.37M | 388.05M | 263.33M | 258.68M | 201.87M | 156.58M | 97.39M | 91.73M |
| Capital Expenditures | -31.36M | -36.55M | -36.65M | -36.88M | -28.27M | -31.34M | -17.91M | -16.02M | -11.72M | -13.54M |
| Investing Cash Flow | -31.14M | -28.31M | -34.63M | -38.74M | -31.36M | -31.21M | -19.14M | -16.97M | -12.24M | -13.42M |
| Share Repurchases | -917.39M | -169.87M | -144.02M | -847.85M | -62.10M | -98.27M | 0 | 0 | -155.58M | 0 |
| Debt Issued | — | — | — | — | — | — | — | 0 | 0 | 164.51M |
| Debt Repaid | — | — | — | — | 0 | 0 | -80.44M | -72.19M | -12.38M | -390.06M |
| Financing Cash Flow | -860.39M | -154.01M | -182.64M | -775.77M | -44.45M | -82.28M | -73.92M | -141.58M | -97.83M | -58.01M |
| Net Change in Cash | -172.39M | 423.99M | 217.18M | -433.04M | 183.54M | 145.85M | 108.64M | -3.21M | -10.91M | 19.67M |
| Free Cash Flow | 681.87M | 572.27M | 396.73M | 351.17M | 235.06M | 227.34M | 183.96M | 140.56M | 85.66M | 78.19M |
This table shows 10 annual periods of Medpace's cash flow statement, from FY 2025 back to FY 2016, across 13 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MEDP's reporting calendar. What is a cash flow statement?